Elucid

A major milestone for Elucid: FFR-IQ™ is now FDA-cleared and commercially available! Read the full announcement: elucid.com/elucid-announc…

We're proud to introduce BioIntegrated FFR-CT, a new approach to noninvasive coronary physiology assessment that integrates coronary anatomy and plaque composition to support more accurate, personalized treatment decisions.
In the ELUCIDATE FFR-CT study, FFR-IQ demonstrated:
· 92.2% sensitivity
· 93.1% specificity
· The highest reported diagnostic performance among FDA-cleared FFR-CT validation studies.¹

Together, FFR-IQ™ and Plaque-IQ™ bring coronary anatomy, plaque biology, and physiology into one comprehensive platform, enabling physicians to better understand both individual lesions and the patient's broader coronary disease from a single CCTA.

📍 Join us at #TCT2026, where results from the ELUCIDATE FFR-CT study will be presented on November 1. Visit us at booth #3424 to learn more.

¹ Elucid FFR-IQ (B.1). FDA 510(k) Summary, K262015. September 29, 2026. Highest reported performance among FDA-cleared FFR-CT validation studies.

#Elucid #FFRIQ #FFRCT #cardiovascularimaging #CCTA #cardiology #precisionmedicine #TCT2026

From TCT to AHA: Following an exciting week at #TCT2026, we're bringing the momentum to American Heart Association #ScientificSessions26 in Chicago! With the recent FDA clearance of FFR-IQ™ and compelling new results from the ELUCIDATE study, we're excited to showcase how Elucid is advancing a more complete approach to coronary artery disease assessment.

Our BioIntegrated FFR-CT approach brings together coronary anatomy and quantitative plaque characteristics to estimate physiology using technology trained against invasive FFR. Together, Plaque-IQ™ and FFR-IQ™ help clinicians move beyond anatomy alone, combining plaque burden, composition, stenosis assessment, and coronary physiology into a more comprehensive view of disease.

📍 Join us at #AHA26 at Booth 3018!
Meet the team and experience our latest technology firsthand.

#ELUCIDATE #FFRCT #CCTA #cardiovascularimaging #PlaqueIQ #FFRIQ

That's a wrap at #TCT2026! Thanks to all of the physicians and partners who stopped by to check out our newly FDA-cleared Biolntegrated FFR-CT product, and to chat about the latest performance data from ELUCIDATE! It's been a blast. Until next time... but find us at #AHA2026 and #RSNA2026 fast-approaching right around the corner!

A new chapter in FFR-CT: We're proud to announce results from ELUCIDATE, the pivotal validation study supporting FDA clearance of Elucid's FFR-IQ™ technology, presented at #TCT2026!

The international, multicenter study demonstrated:
- 92.9% vessel-level diagnostic accuracy against invasive FFR
- 92.2% sensitivity and 93.1% specificity, the highest reported in an FFR-CT validation study
- Strong performance in the clinical gray zone
Evaluating 491 coronary vessels across 11 U.S. and European institutions, ELUCIDATE highlights the potential of a fundamentally different approach to noninvasive coronary physiology.

Powered by deep learning and trained against invasive FFR, Biolntegrated FFR-IQ brings together coronary anatomy and plaque biology to estimate physiology.

Together with Plaque-IQ™, this represents an important step toward a more complete, personalized understanding of coronary artery disease.

Read the full announcement: elucid.com/elucidate-stud…

#ELUCIDATE #FFRIQ #FFRCT #CCTA #cardiovascularimaging

Have questions from our #TCT2026 sessions or want more hands-on time? We’re at booth 3424 to chat! Come by to learn how our BioIntegrated FFR-CT and its features can support PCI planning.

#interventionalcardiology #cardiology #ELUCIDATE